恩替卡韦治疗后慢性乙型肝炎患者天冬氨酸转氨酶与血小板比值及瞬时弹性成像动态变化对组织学应答的预测
148例慢性乙型肝炎患者接受恩替卡韦治疗96周,治疗前后行肝活检和FibroScan。肝硬度值和AST与血小板比值随METAVIR评分升高而增加(P < .001),治疗后均显著下降;肝硬度值下降预测组织学应答的AUC为0.70,AST与血小板比值下降的AUC为0.77。结论认为两者可有效预测组织学应答,用于抗病毒治疗监测以减少肝活检。
要点
- 肝硬度值和AST与血小板比值随METAVIR评分从F0至F4升高而显著增加(P < .001)。
- 恩替卡韦治疗96周后,FibroScan肝硬度值和AST与血小板比值均显著下降。
- AST与血小板比值下降预测组织学应答的AUC为0.77,肝硬度值下降的AUC为0.70。
核心结论
- AST与血小板比值和FibroScan值均能有效预测慢性乙型肝炎患者恩替卡韦治疗期间的组织学应答,可用于抗病毒治疗监测以避免多次肝活检。
研究设计与样本
- 共纳入148例慢性乙型肝炎患者,所有患者在恩替卡韦治疗前及治疗96周后接受肝活检和FibroScan检查,并收集患者信息。
关键影像表现/征象
- 基线肝活检显示无肝纤维化(F0)7例(4.7%),轻度肝纤维化(F1)51例(34.5%),进展性肝纤维化(>F1)90例(60.9%)。
- 肝硬度值和AST与血小板比值随METAVIR评分从F0至F4升高而显著增加(P < .001)。
- 恩替卡韦治疗96周后,FibroScan测得的平均肝硬度值和AST与血小板比值均显著下降。
诊断标准与关键数值
- 肝硬度值下降预测组织学应答的AUC为0.70(95%CI 0.61-0.79;P < .001),敏感度74.3%,特异度68.8%。
- AST与血小板比值下降预测组织学应答的AUC为0.77(95%CI 0.69-0.86;P < .001),敏感度76.2%,特异度70.2%。
- 多因素分析显示高HBV DNA病毒载量(OR 1.44;P = .04)和高METAVIR评分(OR 1.38;P = .02)是组织学应答的独立危险因素。
临床应用与阅片要点
- AST与血小板比值和FibroScan值可用于慢性乙型肝炎患者恩替卡韦抗病毒治疗期间的组织学应答监测,以减少多次肝活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the dynamic changes of the aspartate aminotransferase (AST)-to-platelet ratio and transient elastography (FibroScan; Echosens, Paris, France) in predicting a histologic response in patients with chronic hepatitis B (CHB) after entecavir treatment.
METHODS: A total of 148 patients with CHB were enrolled. Patient information was collected. All patients received liver biopsy and FibroScan before and after 96 weeks of entecavir treatment.
RESULTS: Baseline liver biopsy results showed that there were 7 patients without liver fibrosis (fibrosis stage F0; 4.7%), 51 patients with mild liver fibrosis (F1; 34.5%), and 90 patients with advanced liver fibrosis (>F1; 60.9%). The liver stiffness value and AST-to-platelet ratio increased significantly as the METAVIR score of the patients increased from F0 to F4 (P < .001). After antiviral therapy for 96 weeks, the average liver stiffness value measured by FibroScan and the AST-to-platelet ratio showed a significant decrease. When we use a decreased liver stiffness value to predict a histologic response, the area under the receiver operating characteristic curve was 0.70 (95% confidence interval, 0.61-0.79; P < .001), and the sensitivity and specificity were 74.3% and 68.8%, respectively. The decrease of the AST-to-platelet ratio also could predict the histologic response of patients with CHB; the area under the receiver operating characteristic curve was 0.77 (95% confidence interval, 0.69-0.86; P < .001) with sensitivity of 76.2% and specificity of 70.2%. A multivariate analysis indicated that a high hepatitis B virus DNA viral load (odds ratio, 1.44; P = .04) and high METAVIR score (odds ratio, 1.38; P = .02) were independent risk factors for the histologic response.
CONCLUSIONS: Both the AST-to-platelet ratio and FibroScan value can effectively predict a histologic response in patients with CHB during entecavir treatment. Therefore, they can be used to monitor these patients during antiviral treatment to avoid multiple liver biopsies.
引用
- Sun J, Li Y, Sun X, et al. Dynamic Changes of the Aspartate Aminotransferase-to-Platelet Ratio and Transient Elastography in Predicting a Histologic Response in Patients With Chronic Hepatitis B After Entecavir Treatment. J Ultrasound Med. 2018. PMID: 30244494. doi:10.1002/jum.14822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。